MOLECULAR MECHANISM OF HEMATOLOGICAL MALIGNANCY
血液恶性肿瘤的分子机制
基本信息
- 批准号:2097075
- 负责人:
- 金额:$ 25.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1992
- 资助国家:美国
- 起止时间:1992-03-04 至 1996-02-28
- 项目状态:已结题
- 来源:
- 关键词:T lymphocyte acute lymphocytic leukemia athymic mouse cell line chondrocytes complementary DNA disease /disorder model gene expression gene frequency gene induction /repression gene mutation human tissue laboratory mouse laboratory rat neoplasm /cancer genetics neoplasm /cancer relapse /recurrence neoplasm /cancer transplantation nucleic acid sequence oncogenes phenotype polymerase chain reaction retinoblastoma tissue /cell culture tumor suppressor genes
项目摘要
The mechanism of induction of acute lymphoblastic leukemia (T-ALL) is
not known. Nor do we know why T-ALL patients relapse with such high
frequency. If the molecular mechanism of induction and of relapse of
T-ALL were understood, it might be possible to design rational
strategies to reverse or cure this disease. Different mechanisms for
the induction of T-ALL have been proposed. One reasonable suggestion
targets dysregulation of differentiation as an initiating event.
Disregulation of differentiation of pro- or pre- T cells would cause
unscheduled cellular self-renewal and the abrogation of cell
senescence. In this application we show that dysregulation of
differentiation may be associated with the loss or mutation of
specific tumor suppressor (TS) genes. A study of the status of two
known TS genes in T-ALL cell lines has revealed that 60% of T-ALL
lines possessed mutated p53 TS genes, and 20% had lost the
retinoblastoma susceptibility gene product Rb. Furthermore, fresh T-
ALL samples have also been found to possess mutations of the p53
gene. The high incidence of loss of these TS genes among T-ALL
cells, and the relationship between the roles of p53/Rb and cell
differentiation/proliferation strongly suggest that mutation/loss of
the p53/RB genes, respectively, plays a significant role in the
induction and/or the recurrence of T-ALL. Therefore we propose to
study the mechanism of induction of T-ALL (i) by studying the status
of p53 in primary diagnosis and relapse T-ALL patient samples; (ii)
By studying the status of p53 in primary diagnosis and relapse
samples of the same patients to determine the relationship of p53
mutation and T-ALL cell "progression"; (iii) By studying the effects
of p53 on the differentiation of leukemic T blasts; and (iv) by
designing strategies for reversing the leukemic state of T-ALL cells
through the introduction of wild type p53 and/or Rb gene constructs.
Since all malignancy-conferring suppressor genes in T-cell
leukemogenesis appears to be the most promising approach to date for
achieving the biological reversion of the leukemic state.
急性淋巴细胞白血病(T-ALL)的诱导机制是
不知道。 我们也不知道为什么T-ALL患者复发时如此高,
频率. 如果诱导和复发的分子机制
T-ALL都被理解了,也许有可能设计出合理的
逆转或治愈这种疾病的策略。 的不同机制
已经提出了T-ALL的诱导。 一个合理的建议
靶向分化失调作为起始事件。
前T细胞或前T细胞的分化失调会导致
非程序性细胞自我更新和细胞凋亡
衰老 在本申请中,我们表明,
分化可能与以下基因的缺失或突变有关:
特异性肿瘤抑制基因(TS)。 两个国家地位的研究
T-ALL细胞系中已知的TS基因揭示了60%的T-ALL
株系具有突变的p53 TS基因,20%的株系丧失了p53 TS基因。
视网膜母细胞瘤易感基因产物Rb。 此外,新鲜T-
还发现所有样本都具有p53突变,
基因 T-ALL中这些TS基因丢失的高发生率
p53/Rb与细胞凋亡的关系
分化/增殖强烈表明,
p53/RB基因分别在细胞凋亡中起重要作用。
T-ALL的诱导和/或复发。 因此,我们建议
研究T-ALL的诱导机制(i)通过研究
初步诊断和复发T-ALL患者样品中的p53;(ii)
通过研究p53在原发性肝癌和复发性肝癌中的地位,
相同患者的样本,以确定p53
突变和T-ALL细胞“进展”;(iii)通过研究
p53对白血病T母细胞分化的影响;以及(iv)通过
设计逆转T-ALL细胞白血病状态的策略
通过引入野生型p53和/或Rb基因构建体。
由于T细胞中所有的恶性抑制基因
白血病发生似乎是迄今为止最有希望的方法,
实现白血病状态的生物学逆转。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Martin nmi Haas其他文献
Martin nmi Haas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Martin nmi Haas', 18)}}的其他基金
STUDIES OF AN AFRICAN POPULATION ENDEMIC FOR HTLV
非洲人群 HTLV 流行病的研究
- 批准号:
3183737 - 财政年份:1986
- 资助金额:
$ 25.4万 - 项目类别:
STUDIES OF AN AFRICAN POPULATION ENDEMIC FOR HTLV
非洲人群 HTLV 流行病的研究
- 批准号:
3183736 - 财政年份:1986
- 资助金额:
$ 25.4万 - 项目类别:
VIRAL MALIGNANT LYMPHOMAGENESIS IN X-IRRADIATED MICE
X 射线照射小鼠中的病毒恶性淋巴瘤发生
- 批准号:
3171912 - 财政年份:1982
- 资助金额:
$ 25.4万 - 项目类别:
VIRAL MALIGNANT LYMPHOMAGENESIS IN X-IRRADIATED MICE
X 射线照射小鼠中的病毒恶性淋巴瘤发生
- 批准号:
3171917 - 财政年份:1982
- 资助金额:
$ 25.4万 - 项目类别:
VIRAL MALIGNANT LYMPHOMAGENESIS IN X-IRRADIATED MICE
X 射线照射小鼠中的病毒恶性淋巴瘤发生
- 批准号:
3171915 - 财政年份:1982
- 资助金额:
$ 25.4万 - 项目类别:
VIRAL MALIGNANT LYMPHOMAGENESIS IN X-IRRADIATED MICE
X 射线照射小鼠中的病毒恶性淋巴瘤发生
- 批准号:
3171916 - 财政年份:1982
- 资助金额:
$ 25.4万 - 项目类别:
相似海外基金
Understanding of the onset and recurrence pattern of intractable acute lymphocytic leukemia based on clone analysis
基于克隆分析了解难治性急性淋巴细胞白血病的发病和复发模式
- 批准号:
20K08723 - 财政年份:2020
- 资助金额:
$ 25.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR-ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph Positive Acute Lymphocytic Leukemia (ALL).
BCR-ABL 多重耐药突变体的新型抑制剂,用于治疗慢性粒细胞白血病 (CML) 和 Ph 阳性急性淋巴细胞白血病 (ALL)。
- 批准号:
9047400 - 财政年份:2015
- 资助金额:
$ 25.4万 - 项目类别:
The Role of Genetic Variants in Sensitivity to Methotrexate in Acute Lymphocytic Leukemia Survivors
遗传变异在急性淋巴细胞白血病幸存者对甲氨蝶呤敏感性中的作用
- 批准号:
319114 - 财政年份:2014
- 资助金额:
$ 25.4万 - 项目类别:
Fellowship Programs
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的骨髓微环境
- 批准号:
8595788 - 财政年份:2013
- 资助金额:
$ 25.4万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8023518 - 财政年份:2011
- 资助金额:
$ 25.4万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8404025 - 财政年份:2011
- 资助金额:
$ 25.4万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8220724 - 财政年份:2011
- 资助金额:
$ 25.4万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8599754 - 财政年份:2011
- 资助金额:
$ 25.4万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8356701 - 财政年份:2010
- 资助金额:
$ 25.4万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8166720 - 财政年份:2009
- 资助金额:
$ 25.4万 - 项目类别: